p.151 抽出テキスト

severe limb ischemia (CABBAGE Trial). Ann Vasc Surg 2017; 45: 22-28. PMID: 28600024 678. Tamura K, Tsurumi-Ikeya Y, Wakui H, et al. Therapeutic potential of low-density lipoprotein apheresis in the management of peripheral artery disease in patients with chronic kidney disease. Ther Apher Dial 2013; 17: 185-192. PMID: 23551675 679. Hara T, Kiyomoto H, Hitomi H, et al. Low-density lipoprotein apheresis for haemodialysis patients with peripheral arterial disease reduces reactive oxygen species production via suppression of NA- DPH oxidase gene expression in leucocytes. Nephrol Dial Transplant 2009; 24: 3818-3825. PMID: 19617260 680. Tsurumi-Ikeya Y, Tamura K, Azuma K, et al. Sustained inhibition of oxidized low-density lipoprotein is involved in the long-term therapeutic effects of apheresis in dialysis patients. Arterioscler Thromb Vasc Biol 2010; 30: 1058-1065. PMID: 20203302 681. Kobayashi S, Oka M, Moriya H, et al. LDL-apheresis reduces P-Selectin, CRP and fibrinogen - Possible important implications for improving atherosclerosis. Ther Apher Dial 2006; 10: 219-223. PMID: 16817784 682. Kizaki Y, Ueki Y, Yoshida K, et al. Does the production of nitric oxide contribute to the early improvement after a single low-density lipoprotein apheresis in patients with peripheral arterial obstructive disease? Blood Coagul Fibrinolysis 1999; 10: 341-349. PMID: 10493215 683. Murashima J, Ueki Y, Matsunaga Y, et al. Removal of low-density lipoprotein from plasma by adsorption increases bradykinin and plasma nitric oxide levels in patients with peripheral atherosclerosis. Blood Coagul Fibrinolysis 1998; 9: 725-732. PMID: 9890715 684. Kobayashi S, Moriya H, Maesato K, et al. LDL-apheresis improves peripheral arterial occlusive disease with an implication for anti-inflammatory effects. J Clin Apher 2005; 20: 239-243. PMID: 15880405 685. 医薬品医療機器総合機構.医療機器.https://www.pmda.go.jp/ review-services/drug-reviews/review-information/devices/0019.html 686. Naoum JJ, Arbid EJ. Spinal cord stimulation for chronic limb ischemia. Methodist Debakey Cardiovasc J 2013; 9: 99-102. PMID: 23805343 687. Ubbink DT, Vermeulen H. Spinal cord stimulation for non-reconstructable chronic critical leg ischaemia. Cochrane Database Syst Rev 2013: CD004001. PMID: 23450547 688. Stoekenbroek RM, Santema TB, Legemate DA, et al. Hyperbaric oxygen for the treatment of diabetic foot ulcers: A systematic review. Eur J Vasc Endovasc Surg 2014; 47: 647-655. PMID: 24726143 689. Murad MH, Altayar O, Bennett M, et al. Using GRADE for evaluating the quality of evidence in hyperbaric oxygen therapy clarifies evidence limitations. J Clin Epidemiol 2014; 67: 65-72. PMID: 24189086 690. Faglia E, Favales F, Aldeghi A, et al. Adjunctive systemic hyperbaric oxygen therapy in treatment of severe prevalently ischemic diabetic foot ulcer: A randomized study. Diabetes Care 1996; 19: 1338- 1343. PMID: 8941460 691. Abidia A, Laden G, Kuhan G, et al. The role of hyperbaric oxygen therapy in ischaemic diabetic lower extremity ulcers: a double-blind randomised-controlled trial. Eur J Vasc Endovasc Surg 2003; 25: 513-518. PMID: 12787692 692. Löndahl M, Katzman P, Nilsson A, et al. Hyperbaric oxygen therapy facilitates healing of chronic foot ulcers in patients with diabetes. Diabetes Care 2010; 33: 998-1003. PMID: 20427683 693. Margolis DJ, Gupta J, Hoffstad O, et al. Lack of effectiveness of hyperbaric oxygen therapy for the treatment of diabetic foot ulcer and the prevention of amputation: A cohort study. Diabetes Care 2013; 36: 1961-1966. PMID: 23423696 694. Santema KTB, Stoekenbroek RM, Koelemay MJW, et al. DAMO- 2CLES Study Group. Hyperbaric oxygen therapy in the treatment of ischemic lower- extremity ulcers in patients with diabetes: Results of the DAMO2CLES multicenter randomized clinical trial. Diabetes Care 2018; 41: 112-119. PMID: 29074815 695. Sanni A, Hamid A, Dunning J. Is sympathectomy of benefit in critical leg ischaemia not amenable to revascularisation? Interact Cardiovasc Thorac Surg 2005; 4: 478-483. PMID: 17670461 696. Barnes RW, Baker WH, Shanik G, et al. Value of concomitant sympathectomy in aortoiliac reconstruction: Results of a prospective, randomized study. Arch Surg 1977; 112: 1325-1330. PMID: 921531 697. Cross FW, Cotton LT. Chemical lumbar sympathectomy for ischemic rest pain: A randomized, prospective controlled clinical trial. Am J Surg 1985; 150: 341-345. PMID: 3898891 698. Moran PS, Teljeur C, Harrington P, et al. A systematic review of in-

termittent pneumatic compression for critical limb ischaemia. Vasc Med 2015; 20: 41-50. PMID: 25270409 699. Labropoulos N, Wierks C, Suffoletto B. Intermittent pneumatic

compression for the treatment of lower extremity arterial disease: a systematic review. Vasc Med 2002; 7: 141-148. PMID: 12402994 700. Sultan S, Hamada N, Soylu E, et al. Sequential compression biomechanical device in patients with critical limb ischemia and nonreconstructible peripheral vascular disease. J Vasc Surg 2011; 54: 440- 447. PMID: 21571490 701. Kavros SJ, Delis KT, Turner NS, et al. Improving limb salvage in critical ischemia with intermittent pneumatic compression: A controlled study with 18-month follow-up. J Vasc Surg 2008; 47: 543- 549. PMID: 18295105 702. Morishita R, Makino H, Aoki M, et al. Phase I/IIa clinical trial of therapeutic angiogenesis using hepatocyte growth factor gene transfer to treat critical limb ischemia. Arterioscler Thromb Vasc Biol 2011; 31: 713-720. PMID: 21183732 703. Makino H, Aoki M, Hashiya N, et al. Long-term follow-up evaluation of results from clinical trial using hepatocyte growth factor gene to treat severe peripheral arterial disease. Arterioscler Thromb Vasc Biol 2012; 32: 2503-2509. PMID: 22904270 704. Powell RJ, Simons M, Mendelsohn FO, et al. Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation 2008; 118: 58-65. PMID: 18559703 705. Shigematsu H, Yasuda K, Iwai T, et al. Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Ther 2010; 17: 1152-1161. PMID: 20393508 706. Yonemitsu Y, Matsumoto T, Itoh H, et al. DVC1-0101 to treat peripheral arterial disease: A Phase I/IIa open-label dose-escalation clinical trial. Mol Ther 2013; 21: 707-714. PMID: 23319060 707. Walter DH, Krankenberg H, Balzer JO, et al. PROVASA Investigators. Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: A randomized-start, placebo-controlled pilot trial (PROVASA). Circ Cardiovasc Interv 2011; 4: 26-37. PMID: 21205939 708. Teraa M, Sprengers RW, Schutgens RE, et al. Effect of repetitive intra-arterial infusion of bone marrow mononuclear cells in patients with no-option limb ischemia: The randomized, double-blind, placebo-controlled Rejuvenating Endothelial Progenitor Cells via Transcutaneous Intra-arterial Supplementation (JUVENTAS) trial. Circulation 2015; 131: 851-860. PMID: 25567765 709. Tateishi-Yuyama E, Matsubara H, Murohara T, et al. Therapeutic Angiogenesis using Cell Transplantation (TACT) Study Investigators. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 2002; 360: 427-435. PMID: 12241713 710. Kondo K, Yanishi K, Hayashida R, et al. TACT Follow-up Study Investigators. Long-Term Clinical Outcomes Survey of Bone Marrow-Derived Cell Therapy in Critical Limb Ischemia in Japan. Circ J 2018; 82: 1168-1178. PMID: 29386474 711. Horie T, Yamazaki S, Hanada S, et al. Outcome From a Randomized Controlled Clinical Trial - Improvement of Peripheral Arterial Disease by Granulocyte Colony-Stimulating Factor-Mobilized Autologous Peripheral-Blood-Mononuclear Cell Transplantation (IMPACT). Circ J 2018; 82: 2165-2174. PMID: 29877199 712. Kawamoto A, Katayama M, Handa N, et al. Intramuscular transplantation of G-CSF-mobilized CD34(+) cells in patients with critical limb ischemia: A phase I/IIa, multicenter, single-blinded, dose-escalation clinical trial. Stem Cells 2009; 27: 2857-2864. PMID: 19711453 713. Fujita Y, Kinoshita M, Furukawa Y, et al. Phase II clinical trial of CD34+ cell therapy to explore endpoint selection and timing in patients with critical limb ischemia. Circ J 2014; 78: 490-501. PMID: 24257136 714. Losordo DW, Kibbe MR, Mendelsohn F, et al. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circ Cardiovasc Interv 2012; 5: 821-830. PMID: 23192920 715. Ohtake T, Mochida Y, Ishioka K, et al. Autologous Granulocyte Colony-Stimulating Factor-Mobilized Peripheral Blood CD34 Positive Cell Transplantation for Hemodialysis Patients with Critical Limb Ischemia: A Prospective Phase II Clinical Trial. Stem Cells Transl Med 2018; 7: 774-782. PMID: 30059194 716. Peeters Weem SM, Teraa M, de Borst GJ, et al. Bone Marrow derived Cell Therapy in Critical Limb Ischemia: A Meta-analysis of Randomized Placebo Controlled Trials. Eur J Vasc Endovasc Surg 2015; 50: 775-783. PMID: 26460286 717. Rigato M, Monami M, Fadini GP. Autologous Cell Therapy for Pe-